Insider Trading Alert - Dendreon And 4 Others Traded By Insiders

Yesterday, July 3, 2013, 389 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $200.00 to $15,089,002.16.

Highlighted Stocks Traded by Insiders:

Dendreon (DNDN) - FREE Research Report

Monteith William who is EVP, Technical Operations at DENDREON CORP sold 128 shares at $4.12 per share for a total value of $527.36 on June 30, 2013. Following this transaction, the EVP, Technical Operations owned 155,913 shares meaning that the stake was reduced by 0.08% with the 128 share sell-off.

The shares most recently traded at $4.30, down $0.09, or 2.05% since the insider transaction.

The average volume for Dendreon has been 4.3 million shares per day over the past 30 days. Dendreon has a market cap of $677.7 million and is part of the health care sector and drugs industry. Shares are down 18.71% year to date as of the close of trading on Tuesday.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Currently there are 2 analysts that rate Dendreon a buy, 8 analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DNDN - FREE

TheStreet Quant Ratings rates Dendreon as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Dendreon Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes